Optas LLC Acquires 164 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Optas LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,904 shares of the medical research company’s stock after acquiring an additional 164 shares during the quarter. Optas LLC’s holdings in Thermo Fisher Scientific were worth $1,178,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Lincoln National Corp raised its stake in Thermo Fisher Scientific by 6.8% in the first quarter. Lincoln National Corp now owns 7,810 shares of the medical research company’s stock valued at $4,539,000 after purchasing an additional 496 shares in the last quarter. FORA Capital LLC raised its stake in Thermo Fisher Scientific by 5.4% in the first quarter. FORA Capital LLC now owns 10,626 shares of the medical research company’s stock valued at $6,176,000 after purchasing an additional 542 shares in the last quarter. Salomon & Ludwin LLC raised its stake in Thermo Fisher Scientific by 5.6% during the first quarter. Salomon & Ludwin LLC now owns 1,550 shares of the medical research company’s stock worth $901,000 after acquiring an additional 82 shares in the last quarter. Diversified LLC raised its stake in Thermo Fisher Scientific by 20.1% during the first quarter. Diversified LLC now owns 939 shares of the medical research company’s stock worth $546,000 after acquiring an additional 157 shares in the last quarter. Finally, Whittier Trust Co. raised its stake in Thermo Fisher Scientific by 1.6% during the first quarter. Whittier Trust Co. now owns 85,611 shares of the medical research company’s stock worth $49,757,000 after acquiring an additional 1,347 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at $7,134,197.76. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,300 shares of company stock valued at $6,831,268 over the last ninety days. 0.34% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. TD Cowen boosted their target price on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Sanford C. Bernstein lowered their price objective on Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating for the company in a research note on Thursday, October 24th. Stifel Nicolaus lowered their price objective on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. JPMorgan Chase & Co. upped their price objective on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Finally, Barclays lowered their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $649.33.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $557.92 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. Thermo Fisher Scientific Inc. has a 52-week low of $437.26 and a 52-week high of $627.88. The stock’s 50 day moving average price is $599.39 and its two-hundred day moving average price is $583.51. The stock has a market capitalization of $213.13 billion, a price-to-earnings ratio of 34.98, a PEG ratio of 3.61 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. During the same period in the prior year, the firm earned $5.69 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up .2% on a year-over-year basis. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.